International Journal of Cancer10.1002/ijc.339662022150122038-2045Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability‐high/mismatch repair‐deficient or POLE ‐mutated metastatic or unresectable colorectal cancerChung Ryul Oh, Jeong Eun Kim, Yong Sang Hong, Sun Young Kim, Joong Bae Ahn, Ji Yeon Baek, Myung‐Ah Lee, Myoung Joo Kang, Sang Hee Cho, Seung‐Hoon Beom, Tae Won Kim,,
Gynecologic Oncology10.1016/s0090-8258(22)01353-12022166S80-S81Phase 2 study of tislelizumab monotherapy in previously treated, locally advanced, unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors: Gynecological cancer subgroup (127)Dong Wang, Naiyi Zhang, Aimin Zang, Jing Wang, Yi Huang, Lin Shen, Jian Li, Yanqiao Zhang, Tianshu Liu, Yanhong Deng, Yaling Xu, Zhezhen Li, Yidi Wang, Yunong Gao,
Frontiers in Oncology10.3389/fonc.2023.1113346202313The cost-effectiveness analysis of serplulimab versus regorafenib for treating previously treated unresectable or metastatic microsatellite instability-high or deficient mismatch repair colorectal cancer in ChinaYue Ma, Jiting Zhou, Yuxin Ye, Xintian Wang, Aixia Ma, Hongchao Li
ESMO Open10.1016/j.esmoop.2021.100145202163100145The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancerA. Trullas, J. Delgado, A. Genazzani, J. Mueller-Berghaus, C. Migali, S. Müller-Egert, H. Zander, H. Enzmann, F. Pignatti,
Value in Health10.1016/j.jval.2022.09.66220222512S137EE416 Cost-Effectiveness of Pembrolizumab Monotherapy for First-Line Treatment in Adult Patients with Microsatellite Instability High/Mismatch Repair-Deficient Metastatic Colorectal Cancer From a French PerspectiveR Aguiar-Ibáñez, L Cagnan, L Bensimon, C Mamane, E Lebbink, C Crossan, D Tougeron, C De la Fouchardière, M Amonkar,
10.21203/ analysis of pembrolizumab versus chemotherapy as the first-line treatment in patients with mismatch-repair-deficient (dMMR) or microsatellite- instability-high (MSI-H) advanced or metastatic colorectal cancer from a perspective of health care system in ChinaCHEN ZHU, Gang Han, Bin Wu,
European Journal of Cancer10.1016/j.ejca.2020.11.00920211449-16Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancerRaphael Colle, Anna Radzik, Romain Cohen, Anna Pellat, Daniel Lopez-Tabada, Marine Cachanado, Alex Duval, Magali Svrcek, Yves Menu, Thierry André,
Canadian Journal of Gastroenterology and Hepatology10.1155/2023/8370262202320231-6Are High Levels of Microsatellite Instability and Microsatellite Stability Identical in DNA Mismatch Repair-Deficient Colorectal Cancer Patients?Yan-Yu Qiu, Yi-Xin Zeng, Yong Cheng,,
Journal for ImmunoTherapy of Cancer10.1136/jitc-2020-001499202082e001499RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II studyRomain Cohen, Jaafar Bennouna, Aurélia Meurisse, Christophe Tournigand, Christelle De La Fouchardière, David Tougeron, Christophe Borg, Thibault Mazard, Benoist Chibaudel, Marie-Line Garcia-Larnicol, Magali Svrcek, Dewi Vernerey, Yves Menu, Thierry André
Clinical Colorectal Cancer10.3816/ccc.2010.n.028201094193-194Microsatellite Instability and Mismatch Repair Genes in Colorectal Cancer: Useful Tools for Managing Patients and Counseling Their RelativesJean-Yves Douillard,